Oral session 4

  • Location:
  • Chairs:
     G. Prins, Chicago (US)
     E. Zwarthoff, Rotterdam (NL)
Biological efficacy of a Stat3 inhibitor in combination with Docetaxel in patient-derived xenografts of prostate cancer
 M-C. Labarthe, York (GB)
Efficiency of PARP inhibitors in different progression and treatment stages of prostate cancer
 F.R. Santer, Innsbruck (AT)
Multimodality imaging of a novel spontaneous prostate cancer liver metastasis model
 S. Roobol, Rotterdam (NL)
Mechanisms of nuclear import of the Androgen Receptor splice variants and their contribution to progression of castration-resistant prostate cancer
 M. Luna Velez, Nijmegen (NL)